Your drug from development to GDP-compliant distribution. From a single source.

The 2022 version of the EU GMP Guide Annex 1 requires a documented contamination control strategy that brings together all contamination-relevant elements of a site: facility and cleanroom design, personnel and material flow, environmental monitoring, barrier and isolator technology, and the underlying quality risk management per ICH Q9. What matters is not the sum of the individual measures, but the evidence that they work as a coherent concept.

FDA inspections assess against 21 CFR Part 210/211 and, where deficiencies are found, end with Form 483 observations and, if escalated, a warning letter. EU inspections assess against the EU GMP Guide (EudraLex Volume 4) and, where deficiencies are found, lead to an inspection report and, if escalated, a statement of non-compliance with consequences for the GMP certificate. The two overlap heavily in substance; preparation, however, must understand the respective procedure, documentation language, and escalation logic.

A risk-based validation per GAMP 5 is the foundation, but it only covers 21 CFR Part 11 and the EU GMP Guide Annex 11 once audit trail configuration, access controls, and electronic signatures are explicitly tested and regularly reviewed during ongoing operations. Data integrity per ALCOA+ is a continuous process, not a one-time validation record.

The clean handover of process knowledge. The EU GMP Guide Annex 15 requires qualification and validation of the new facility; the process performance qualification demonstrates reproducible manufacturing at the target scale. When a transfer fails, it is rarely the technology that is at fault, but the fact that the rationale for critical process parameters from development per ICH Q8 to Q10 was not documented in a traceable way at the new scale.

The EU GDP Guidelines 2013/C 343/01 require that the declared storage conditions are maintained across the entire supply chain and substantiated through temperature mapping and continuous monitoring, including at the handover between the parties involved. The basis is a documented quality system with a designated responsible person per § 52a AMG. For biologics and vaccines, the qualified cold chain thereby becomes a critical part of product quality.